

30 Oct 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: BMS looks to new launches amid patent losses; Novartis prioritizes high-value medicines and the US market; Biogen learns from Aduhelm experience; J&J builds myeloma franchise; and Asian bioventures debate best strategies.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 October 2022, including: [*Bristol Myers Squibb Company*](#) looks to new launches amid patent losses; [*Novartis AG*](#) prioritizes high-value medicines and the US market; [*Biogen, Inc.*](#) learns from Aduhelm experience; [*Johnson & Johnson*](#) builds myeloma franchise; and Asian bioventures debate best strategies.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*All Eyes On Bristol's New Launches*](#)" - Scrip, 26 Oct, 2022.)

(Also see "[*Weak Spots Blight Novartis Third Quarter As New Products Shine*](#)" - Scrip, 25 Oct, 2022.)

(Also see "[*Biogen Weighs Aduhelm Lessons Ahead Of Lecanemab Launch*](#)" - Scrip, 25 Oct, 2022.)

(Also see "[*J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval*](#)" - Scrip, 26 Oct, 2022.)

(Also see "[*How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders*](#)" - Scrip, 24

Oct, 2022.)

[Click here to explore this interactive content online](#) ✎